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Paller et al 495Results: More crisaborole- than vehicle-treated patients achieved ISGA score success (clear/almost clear
with $2-grade improvement; AD-301: 32.8% vs 25.4%, P = .038; AD-302: 31.4% vs 18.0%, P\ .001), with a
greater percentage with clear/almost clear (51.7% vs 40.6%, P = .005; 48.5% vs 29.7%, P \ .001).
Crisaborole-treated patients achieved success in ISGA score and improvement in pruritus earlier than those
treated with vehicle (both P # .001). Treatment-related adverse events were infrequent and mild to
moderate in severity.Limitations: Short study duration was a limitation.Conclusions: Crisaborole demonstrated a favorable safety profile and improvement in all measures
of efficacy, including overall disease severity, pruritus, and other signs of AD. ( J Am Acad Dermatol
2016;75:494-503.)
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d Phosphodiesterase 4 regulates
inflammation and is overactive in atopic
dermatitis.
d In two phase III studies, crisaborole
ointment, a novel phosphodiesterase 4
inhibitor, improved disease severity and
pruritus with a favorable safety profile in
patients with mild to moderate atopic
dermatitis.
d Crisaborole represents a promising,
nonsteroidal topical treatment to
improve management of atopic
dermatitis.Atopic dermatitis (AD), a
complex chronic inflamma-
tory skin disease chara-
cterized by erythematous,
eczematous lesions and
often intense pruritus,1-3 is
prevalent worldwide and
affects both children and
adults, with up to 90% of
patients presenting with
mild to moderate disease.4,5
AD-associated pruritus re-
sults in frequent scratching
and contributes significant
psychological, social, and
quality-of-life burdens to
patients and their families.6-8
It also generates a substantial
financial burden, with cost
estimates of up to $3.8 billion annually in the
United States alone.9 More than 80% of children
with AD have persistence of symptoms into their
adult years, a percentage much higher than
previously appreciated.10 In addition, AD is often
associated with significant comorbidities, including
asthma and allergic rhinitis.1,2,8
Topical treatments are commonly prescribed to
alleviate AD symptoms, reduce inflammation, and
prevent flares,11 but no new molecules have been
approved for the treatment of AD in the past 15 years,
and treatment guidelines recommend the use of
topical corticosteroids (TCS), topical calcineurin
inhibitors (TCI), or both.3,8 Despite their efficacy,
both TCS and TCI are associated with limitations in
their use as a result of application reactions and
safety concerns with long-term use. Long-term TCS
use is restricted to avoid local cutaneous atrophy
(especially in sensitive and thin-skinned areas
such as face and groin), striae formation, and
systemic side effects,3,8 TCIs are associated withburning/stinging upon appli-
cation and require enhanced
patient education because
of a boxed warning for
increased risk of lym-
phoma.3,8,12,13 Hence, novel
topical therapies that may
potentially improve upon
the risk-benefit profile of
current therapies are needed.
Phosphodiesterase4(PDE4)
is a key regulator of inflamma-
tory cytokine production in
AD through the degradation
of cyclic adenosine mono-
phosphate.14,15 PDE4 activity
is increased in circulating
inflammatory cells of patients
with AD,16-19 and the inhibi-tion of PDE4 in monocytes in vitro has demonstrated
reduction in the release of proinflammatory cyto-
kines.20 The oral PDE4 inhibitor apremilast was
recently approved for treatment of moderate to severe
plaque psoriasis and psoriatic arthritis, but requires
dose titration to avoid gastrointestinal side effects
(nausea and diarrhea) because of PDE4 inhibition
in nontarget tissues.21,22 A topical PDE4 inhibitor
formulation could address the need for targeted
inhibition of inflammation in skin diseases while
avoiding unwanted side effects.
The novel boron chemistry of crisaborole enables
synthesis of a low-molecular-weight compound
(251 d) that facilitates effective penetration through
human skin.23 Crisaborole enhances cellular control
of inflammation by inhibiting PDE4 and its ability
to degrade intracellular cyclic adenosine mono-
phosphate,15,24-27 thereby suppressing the release
of cytokines by affecting downstream regulation
of the nuclear factor-kB and nuclear factor
of activated T-cell signaling pathways.14,23,28,29
Abbreviations used:
AD: atopic dermatitis
AE: adverse event
ISGA: Investigator’s Static Global Assessment
MedDRA: Medical Dictionary for Regulatory
Activities
PDE4: phosphodiesterase 4
TCI: topical calcineurin inhibitor
TCS: topical corticosteroid
TEAE: treatment-emergent adverse event
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with the percentage of body surface area involved, it
is rapidly and substantially metabolized to inactive
metabolites that have no effect on PDE4 activity or
cytokine release, thus limiting systemic exposure
and reducing the risk of adverse effects.30 Preclinical
analysis in rats and mice revealed that crisaborole is
noncarcinogenic, and early clinical data31-33 demon-
strated a favorable safety profile for crisaborole in
children as young as 2 years of age. Two pivotal
phase III studies were performed to evaluate the
efficacy and safety of crisaborole 2% ointment in
patients aged 2 years of age or older with mild to
moderate AD.METHODS
Study design and oversight
Two identically designed multicenter, random-
ized, double-blind, vehicle-controlled phase III
clinical studies conducted in the United States
(ClinicalTrials.gov AD-301: NCT02118766; AD-302:
NCT02118792) assessed the efficacy and safety of
crisaborole in patients with mild to moderate AD.
Study protocols were developed and conducted, and
data were recorded and reported by the study
sponsor (Anacor Pharmaceuticals, Inc) in accor-
dance with the principles of Good Clinical Practice
and relevant country-specific regulatory require-
ments. At each participating investigational center
(47 and 42 investigational centers for AD-301 and
AD-302, respectively), the institutional review board
approved all study protocols, informed consent/
assent forms, and relevant supporting data. No
participants (principal investigator, study staff,
participants, nor parents/guardians) knew the
treatment assignment, and blinding was maintained
throughout clinical management, data management,
and statistical evaluation until a database lock memo
was issued.Patients
Patients were randomized via the interactive
World Wide Web response system 2:1 toreceive crisaborole:vehicle treatment (Fig 1 and
Supplementary Fig 1). Key inclusion criteria required
patients to be aged 2 years or older and have a
clinical diagnosis of AD according to Hanifin and
Rajka34 criteria, 5% or more treatable body surface
area involvement, and a baseline Investigator’s Static
Global Assessment (ISGA) score of mild (2) or
moderate (3) (Supplementary Fig 1). Key exclusion
criteria prohibited previous use of biologic therapy
or systemic corticosteroids within 28 days or TCS or
TCI use within 14 days. Patients with active skin
infections were excluded (Supplementary Fig 1).
Patients on stable regimens (consistent use$14 days
before day 1) of inhaled corticosteroids, antihista-
mines, and topical retinoids for non-AD lesion
treatment were allowed to continue their medica-
tions. Patients were also allowed to use acceptable
bland emollients to manage dry skin areas around,
but not overlapping, the treatable AD-involved
areas.
Crisaborole ointment treatment
Patients were instructed to apply a layer of study
drug to cover each lesion twice daily throughout the
28-day study to all areas affected by AD at baseline.
The scalp was excluded from treatment to avoid
potential patient dissatisfaction with ointment
application to scalp hair. Patients and caregivers
were provided with documentation for designated
treatment areas at each visit and instructed to apply
additional study drug as needed to newly identified
AD lesions that appeared after day 1. Application
instructions were reviewed at scheduled weekly
in-clinic visits (days 8, 15, and 22).
Evaluation
The primary efficacy end point of success in ISGA
score at day 29 was defined as clear (0) or almost
clear (1) with a 2-grade or more improvement from
baseline (Supplementary Table I). Analysis of the
secondary efficacy end points included the
proportion of patients with an ISGA score of clear
(0) or almost clear (1) at day 29, and time to success
in ISGA score. Additional predefined end points
assessed pruritus severity and signs of AD (erythema,
exudation, excoriation, induration/papulation, and
lichenification). Pruritus severity was recorded twice
daily by the patient or parent/caregiver via electronic
diary. Signs of AD were measured throughout the
treatment period on investigator visit days 1, 8, 15,
22, and 29. Pruritus and signs of AD were measured
on a 4-point scale of none (0), mild (1), moderate (2),
and severe (3) (Supplementary Tables II and III).
Improvement in these measures was defined as
achieving none (0) or mild (1) with a 1-grade or
Fig 1. Atopic dermatitis. Enrollment, randomization, treatment, and follow-up. BSA, Body
surface area; ISGA, Investigator’s Static Global Assessment.
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severity of each sign of AD was calculated as
percentage change from baseline. Primary safety
assessments included adverse events (AEs), vital
signs, and clinical laboratory parameters. All AEs,
including serious AEs, were recorded and classified
by the Medical Dictionary for Regulatory Activities
(MedDRA) at baseline, investigator visit days,
unscheduled doctor visits, and at the end of the
study. Cardiac safety was assessed in a subset of
participants with electrocardiography as a safety
parameter required by the US Food and Drug
Administration.
Statistical analysis
The sample size was selected for efficacy to yield
at least 90% power to achieve a statistically signifi-
cant difference (2-sided test at a = .05), assuming
success rates of 20% (crisaborole-treated group) and
10% (vehicle-treated group). Efficacy analyses were
performed using the intent-to-treat population,
which included all patients randomized and
dispensed study drug, regardless of discontinuation.
The odds ratio of success in ISGA score at day 29 and
secondary end points were tested between treatment
groups using logistic regression with factors fortreatment group and analysis center. Time to success
in ISGA score and time to improvement in pruritus
were analyzed by Kaplan-Meier methods and the
log-rank test. Severity of signs of AD and pruritus
were evaluated using descriptive statistics. The
analyzed safety population included all patients
who were randomized, were confirmed to have
received 1 or more doses of the study drug, and
who received 1 or more postbaseline assessments.
For treatment-emergent AEs (TEAEs), the frequency
of patients with 1 or more TEAEs was tabulated and a
Fisher exact test was performed on any TEAE that
occurred at a frequency of 1% or greater. In addition,
a Fisher exact test was performed for any
treatment-related event that occurred at a frequency
of 1% or greater within any treatment group.
RESULTS
Patients and enrollment
The intent-to-treat population consisted of
503:256 and 513:250 patients randomly assigned to
receive crisaborole:vehicle, for AD-301 and AD-302,
respectively (Supplementary Fig 1). There were no
significant differences across treatment groups or
across studies in baseline demographics and disease
severity (Table I).
Table I. Baseline patient and disease characteristics
Characteristic
AD-301 AD-302
Crisaborole
ointment,
n = 503
Vehicle,
n = 256
Crisaborole
ointment,
n = 513
Vehicle,
n = 250
Age, y
Mean 12.0 12.4 12.6 11.8
Range 2-65 2-63 2-79 2-79
Age groups, %
2-6 y 32.2 30.5 33.7 37.2
7-11 y 30.8 28.5 26.7 28.4
12-17 y 24.1 26.2 24.6 22.8
$18 y 12.9 14.8 15.0 11.6
Sex, %
Male 43.5 44.1 45.0 44.8
Female 56.5 55.9 55.0 55.2
Ethnicity, %
Hispanic or Latino 25.0 25.8 14.4 14.0
Not Hispanic or
Latino
75.0 74.2 85.6 86.0
Race, %
American Indian or
Alaska Native
1.6 1.2 0.6 0.8
Asian 5.2 6.6 5.1 4.0
Black or African
American
27.4 23.8 28.7 31.2
Native Hawaiian or
other Pacific
Islander
0.0 1.6 1.4 1.6
White 61.2 63.3 60.2 57.6
Other 4.6 3.5 4.1 4.8
Baseline ISGA, %
Mild (2) 39.0 36.3 38.4 40.0
Moderate (3) 61.0 63.7 61.6 60.0
% BSA
Mean 18.8 18.6 17.9 17.7
Range 5-95 5-90 5-95 5-90
AD, Atopic dermatitis; BSA, body surface area; ISGA, Investigator’s
Static Global Assessment score.
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More crisaborole-treated patients achieved suc-
cess in ISGA score at day 29 than vehicle-treated
patients (AD-301: 32.8% vs 25.4%, P = .038; AD-302:
31.4% vs 18.0%, P \ .001) (Fig 2, A). In addition,
Kaplan-Meier analysis demonstrated that patients
treated with crisaborole achieved success in ISGA
score earlier than those treated with vehicle ointment
(P\ .001) (Fig 2, B). More patients achieved ISGA
scores of clear (0) or almost clear (1) with crisaborole
at day 29 (AD-301: 51.7% vs 40.6%, P = .005; AD-302:
48.5% vs 29.7%, P\.001) (Fig 2, C ).
Crisaborole improved disease severity as evi-
denced by reduction in signs and symptoms of AD
(Fig 2, D and E ), including pruritus. Crisaborole-
treated patients achieved improvement in pruritus
earlier than vehicle-treated patients (pooled
data, 1.37 vs 1.70 days, P = .001). Across all visits, a
greater proportion of crisaborole-treated patients
achieved improvement in pruritus (pooled data,
days 8, 15, 22: P\ .001; day 29: P = .002) (Fig 3).
For all clinical signs of AD, a greater proportion of
crisaborole-treated patients than vehicle-treated
patients demonstrated improvement at day 29
(Fig 4, A), along with a greater reduction in
mean severity (pooled data, erythema: P \ .001;
exudation: P = .001; excoriation: P \ .001;
induration/papulation: P = .002; lichenification:
P\ .001) (Fig 4, B).
Safety end points
Crisaborole demonstrated a favorable safety
profile in which the majority of TEAEs reported
were mild to moderate in severity (pooled data,
crisaborole: 94.3% of TEAEs; vehicle: 96.9% of
TEAEs), and most were considered unrelated or
unlikely to be related to treatment (pooled data,
crisaborole: 78.6%; vehicle: 84.2%). Treatment
with crisaborole was well tolerated, with similar
rates of TEAEs as vehicle (Table II). The majority
of treatment-related AEs were application site
pain, primarily reported as burning or stinging
(Table II). Application site pain was the only
treatment-related AE that occurred in 1% or more
of patients. Of the patients with application site
pain, 76.7% reported it on the first day of
treatment, and 77.6% had resolution within
1 day of onset. No reports of treatment-related
serious AEs were reported. The rates of study
discontinuation because of AEs were the same
in the crisaborole (1.2%) and vehicle (1.2%)
treatment groups. In addition, no clinically
meaningful differences were observed in patients’
vital signs, electrocardiograms, and clinical labo-
ratory parameters between treatment groups.DISCUSSION
Crisaborole ointment, a novel PDE4 inhibitor,
significantly reduced the signs and symptoms of
AD in children and adults in these two phase III
studies. Its positive efficacy profile was based on: (1)
improvement in disease severity, as early as day 8 of
treatment; (2) reduction in AD signs and symptoms;
and (3) early and sustained improvement in pruritus.
This novel medication showed relief of pruritus,
which is important for AD treatment, as disruption of
the itch-scratch cycle can mitigate AD signs, improve
quality of life,35 and reduce the risk for infection and
scarring.6
The significant efficacy of crisaborole versus
vehicle was noted, despite a strong ‘‘vehicle effect’’
observed in these studies, which is a common
phenomenon in AD clinical studies that compare
Fig 2. Atopic dermatitis (AD). Efficacy analysis. In studies AD-301 and AD-302, a greater
proportion of crisaborole-treated patients achieved success in Investigator’s Static Global
Assessment (ISGA) score by day 29 (A). In addition, crisaborole-treated patients achieved
success in ISGA score earlier than vehicle-treated patients as analyzed by Kaplan-Meier analysis
(pooled) (B). A greater proportion of crisaborole-treated patients achieved an ISGA score of
clear (0) or almost clear (1) by day 29 (C). D and E, Photographs demonstrate success in ISGA
score at day 29.
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Fig 3. Atopicdermatitis (AD). Improvements inpruritus. Inapooledanalysisof studiesAD-301and
AD-302, a greater percentage of crisaborole-treated patients achieved improvement in pruritus at
the earliest evaluation and throughout treatment compared with vehicle-treated patients.
Fig 4. Atopic dermatitis (AD). Improvement in signs of AD. In pooled analysis of AD-301 and
AD-302, comparison of crisaborole-treated with vehicle-treated patients at day 29 revealed a
greater proportion of crisaborole-treated patients achieved improvement in signs of AD (A),
with greater mean reductions in severity from baseline (B).
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example, vehicle-treated patients in a tacrolimus
study demonstrated therapeutic success in 19.5% ofvehicle-treated patients at 4 weeks.36 In treating
patients with AD, a topical medication should ideally
disrupt the inflammatory process and provide
Table II. All treatment-related adverse events and
treatment-emergent adverse events ($1% of
patients)
Crisaborole
ointment,
n = 1012
Vehicle,
n = 499
Treatment-related adverse
event, n (%)
Application site pain* 45 (4.4)y 6 (1.2)
Treatment-emergent adverse
event, n (%)
Gastrointestinal disorders 27 (2.7) 12 (2.4)
Vomiting 15 (1.5) 5 (1.0)
General disorders and
administration site conditions
75 (7.4) 25 (5.0)
Application site pain* 45 (4.4)y 6 (1.2)
Application site pruritus 5 (0.5) 6 (1.2)
Pyrexia 19 (1.9) 7 (1.4)
Infections and infestations 118 (11.7)59 (11.8)
Nasopharyngitis 18 (1.8) 6 (1.2)
Staphylococcal skin infection 1 (0.1)z 5 (1.0)
Upper respiratory tract infection 30 (3.0) 15 (3.0)
Injury, poisoning, and procedural
complications
20 (2.0) 9 (1.8)
Investigationsx 10 (1.0) 6 (1.2)
Nervous system disorders 14 (1.4) 2 (0.4)
Headache 11 (1.1) 1 (0.2)
Respiratory, thoracic, and
mediastinal disorders
47 (4.6) 15 (3.0)
Cough 12 (1.2) 8 (1.6)
Oropharyngeal pain 11 (1.1) 2 (0.4)
Skin and subcutaneous tissue
disorders
37 (3.7) 21 (4.2)
Dermatitis atopic 7 (0.7) 8 (1.6)
*Refers to skin burning or stinging.
yP value for the difference between treatment groups from Fisher
exact test (P = .001).
zP value for the difference between treatment groups from Fisher
exact test (P = .017).
xIncluded clinical laboratory tests, radiologic tests, physical
examination parameters, and physiologic tests.
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including improving the skin barrier to reduce
antigen access and increasing skin hydration by
preventing transepidermal water loss.5 As such,
topical drug vehicles have physiologic cutaneous
effects, adding to the drug effect in improving
outcomes for patients. The incorporation of
crisaborole into the vehicle significantly improved
the efficacy in treating AD on a global scale and in
reducing pruritus and signs of AD.
Because of potential adverse side effects and
restricted long-term use of TCS and TCI, a safe and
efficacious topical alternative is needed to treat AD.
Crisaborole has low systemic absorption and is
quickly metabolized to its inactive metabolites,reducing the risk of systemic side effects, making it
a promising therapeutic alternative to existing
topical therapies.30,33 Twice-daily application of
crisaborole ointment for 28 days demonstrated a
favorable safety profile in these two phase III studies
based on: (1) low incidence of treatment-related AEs,
(2) lack of serious treatment-related AEs, and (3) low
discontinuation rates. The low incidence and mild
severity of AEs observed indicate that the novel
topical formulation of crisaborole allows for targeted
therapy at the site of inflammation while reducing
the risk of systemic side effects observed with oral
PDE4 inhibitors.22 Gastrointestinal AEs, which have
been observed with oral PDE4 inhibitors, were
reported by crisaborole-treated patients at a low
frequency (2.7%) similar to that in vehicle-treated
patients (2.4%) and were not considered treatment
related. Application site burning or stinging is a
commonly reported side effect with TCS or TCI
treatment.37 Although a direct comparison study
with TCS and TCI has yet to be performed, crisabor-
ole ointment demonstrated a low incidence of
application site pain (4.4%), defined by updated
MedDRA guidelines as stinging and/or burning,
compared with rates of application site burning
reported by tacrolimus (20%-58%) and pimecrolimus
(8%-26%).38,39 Crisaborole-treated patients did not
report cutaneous TCS AEs such as telangiectasia or
skin atrophy, but these potential risks only occur
with TCS treatment for 4 weeks or longer.40 The
favorable safety profile demonstrated in these 28-day
studies will be investigated further with a long-term
safety extension study. Overall, twice-daily applica-
tion of crisaborole ointment to all areas of the body
with the exception of the scalp for 28 days demon-
strated a favorable safety profile.
Crisaborole represents a first-in-class nonsteroidal
topical treatment that inhibits overactive PDE4 in AD
to reduce the local inflammation that drives exacer-
bations of the disease.15,24-27 The anti-inflammatory
effect on AD pathology is clear, and crisaborole also
provided early and sustained improvement in pruri-
tus in these two trials. This significant reduction in
pruritus provides additional support to the antipru-
ritic effect observed with other PDE4 inhibitors in
inflammatory skin diseases such as psoriasis.41 The
mechanism through which PDE4 regulates pruritus
is not well understood but is believed to be partially
an indirect result of reducing inflammation,7,42
similar to the antipruritic effects observed with TCS
treatment.42 Preclinical studies have demonstrated
that PDE4 directly regulates pruritus through
reduction of cutaneous neuron43 and dorsal root
ganglion neuron activity.7,44 Mounting evidence in-
dicates that PDE4 inhibitors directly regulate pruritus
J AM ACAD DERMATOL
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for the most troublesome symptom of AD.8,45
Crisaborole represents a promising newoption for
patients with mild to moderate AD based on the
favorable safety profile and improvement in AD seen
in these studies. Future studies could apply alterna-
tive AD severity grading scales that may provide
additional efficacy information by anatomic region to
further our understanding and elaborate on the role
crisaborole could play in the treatment of AD. In
addition, because 45% to 60%of children develop AD
in their first 6 months to 1 year of life, respectively,1
future studies may explore the potential for crisabor-
ole treatment in patients younger than 2 years of age.
Future analysis using the Eczema Area and Severity
Index will provide valuable insight into site-specific
efficacy of crisaborole ointment for comparison with
TCS andTCI. In addition, long-term treatment is often
required because of the chronic nature of AD, and
patients in these two trials were enrolled in an
extension study to evaluate the long-term safety of
crisaborole ointment. Overall, crisaborole ointment
targets the underlying mechanism of the disease and
has the potential to effectively treat AD without the
limitations of current therapies.
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Supplementary Fig 1. Atopic dermatitis (AD). Study design and treatment. Key screening
criteria, patient enrollment, randomization, and assessments. AD, Atopic dermatitis; BID, twice
daily; BSA, body surface area; ECG, electrocardiography; ISGA, Investigator’s Static Global
Assessment; TCI, topical calcineurin inhibitor; TCS, topical corticosteroid. *Proprietary vehicle
developed by Anacor Pharmaceuticals, Inc.
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Supplementary Table I. Investigator’s Static Global Assessment
Scale Grade Definition
0 Clear Minor residual hypopigmentation/hyperpigmentation; no erythema or
induration/papulation; no oozing/crusting
1 Almost clear Trace faint pink erythema, with barely perceptible induration/papulation and no
oozing/crusting
2 Mild Faint pink erythema with mild induration/papulation and no oozing/crusting
3 Moderate Pink-red erythema with moderate induration/papulation with or without oozing/crusting
4 Severe Deep or bright red erythema with severe induration/papulation and with oozing/crusting
To assess the patient’s overall disease severity across all treatable atopic dermatitis lesions, Investigator’s Static Global Assessment (ISGA)
was assessed at screening and days 1, 8, 15, 22, and 29. ISGA was assessed on a 5-point scale from clear (0) to severe (4).
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Supplementary Table II. Severity of pruritus scale
Scale Grade Definition
0 None No itching
1 Mild Occasional, slight itching/scratching
2 Moderate Constant or intermittent itching/scratching that is not disturbing sleep
3 Severe Bothersome itching/scratching that is disturbing sleep
Severity of pruritus was recorded twice daily via electronic diary by patients or caregivers before study drug was applied from days 1-29.
Severity of pruritus was assessed on a 4-point scale from none (0) to severe (3).
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Supplementary Table III. Signs of atopic dermatitis scale
Score Grade Definition
Erythema (redness)
0 None No redness
1 Mild Mildly detectable erythema; pink
2 Moderate Dull red; clearly distinguishable
3 Severe Deep, dark red; marked and extensive
Exudation (oozing and crusting)
0 None No oozing or crusting
1 Mild Minor or faint signs of oozing
2 Moderate Definite oozing or crusting
3 Severe Marked and extensive oozing or crusting
Excoriation (evidence of scratching)
0 None No evidence of excoriation
1 Mild Mild excoriation
2 Moderate Definite excoriation
3 Severe Marked, deep, or extensive excoriation
Induration/papulation
0 None None
1 Mild Slightly perceptible elevation
2 Moderate Clearly perceptible elevation but not extensive
3 Severe Marked and extensive elevation
Lichenification (epidermal thickening)
0 None No epidermal thickening
1 Mild Minor epidermal thickening
2 Moderate Moderate epidermal thickening; accentuated skin lines
3 Severe Severe epidermal thickening; deeply accentuated skin lines
Signs of atopic dermatitis were assessed at every scheduled in-clinic visit from baseline through day 29. Signs of atopic dermatitis were
assessed on a 4-point scale from none (0) to severe (3).
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